ATE306921T1 - Verwendung von cs-866 (olmersartan) zur herstellung eines medikaments für die behandlung von arteriosklerose - Google Patents

Verwendung von cs-866 (olmersartan) zur herstellung eines medikaments für die behandlung von arteriosklerose

Info

Publication number
ATE306921T1
ATE306921T1 AT01124669T AT01124669T ATE306921T1 AT E306921 T1 ATE306921 T1 AT E306921T1 AT 01124669 T AT01124669 T AT 01124669T AT 01124669 T AT01124669 T AT 01124669T AT E306921 T1 ATE306921 T1 AT E306921T1
Authority
AT
Austria
Prior art keywords
arteriosclerosis
treatment
olmersartan
medication
production
Prior art date
Application number
AT01124669T
Other languages
English (en)
Inventor
Yoshio Tsujita
Toshihiko Fujiwara
Toshio Sada
Naoyuki Maeda
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Application granted granted Critical
Publication of ATE306921T1 publication Critical patent/ATE306921T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
AT01124669T 1996-07-15 1997-07-11 Verwendung von cs-866 (olmersartan) zur herstellung eines medikaments für die behandlung von arteriosklerose ATE306921T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18436896 1996-07-15

Publications (1)

Publication Number Publication Date
ATE306921T1 true ATE306921T1 (de) 2005-11-15

Family

ID=16152008

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97930762T ATE283704T1 (de) 1996-07-15 1997-07-11 Pharmazeutische zusammensetzungen enthaltend cs- 866 und insulinresistenz verbesserndem mitteln und deren verwendung zur behandlung von arteriosklerose und xanthom
AT01124669T ATE306921T1 (de) 1996-07-15 1997-07-11 Verwendung von cs-866 (olmersartan) zur herstellung eines medikaments für die behandlung von arteriosklerose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97930762T ATE283704T1 (de) 1996-07-15 1997-07-11 Pharmazeutische zusammensetzungen enthaltend cs- 866 und insulinresistenz verbesserndem mitteln und deren verwendung zur behandlung von arteriosklerose und xanthom

Country Status (18)

Country Link
US (1) US6610682B2 (de)
EP (2) EP1175902B1 (de)
KR (1) KR100540618B1 (de)
CN (2) CN1221259C (de)
AT (2) ATE283704T1 (de)
AU (1) AU714618B2 (de)
CA (1) CA2261040C (de)
CZ (2) CZ300089B6 (de)
DE (2) DE69731840T2 (de)
DK (2) DK0930076T3 (de)
ES (2) ES2250283T3 (de)
HU (2) HU225415B1 (de)
IL (2) IL128059A (de)
NO (2) NO322314B1 (de)
NZ (1) NZ333723A (de)
PT (1) PT930076E (de)
RU (2) RU2220723C2 (de)
WO (1) WO1998002183A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
AU2382601A (en) * 1999-12-24 2001-07-09 Smithkline Beecham Plc Novel method of treatment
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US20040023840A1 (en) * 2000-04-12 2004-02-05 Marc De Gasparo Combination of organic compounds
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
EP1413315A4 (de) * 2001-08-03 2006-08-16 Takeda Pharmaceutical Medikamente mit verzögerter freisetzung
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
JP3874419B2 (ja) * 2003-01-31 2007-01-31 三共株式会社 動脈硬化及び高血圧症の予防及び治療のための医薬
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
EP1685841A1 (de) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prophylaxe und Behandlung von thrombolischen Erkrankungen
RU2441653C2 (ru) * 2005-05-31 2012-02-10 Милан Лэборетериз, Инк. Композиции, содержащие небиволол
WO2007001066A1 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
WO2007039132A1 (de) 2005-10-04 2007-04-12 Bayer Healthcare Ag Neue polymorphe form und die amorphe form von 5-chlor-n- ( { ( 5s ) -2-0x0-3-[4-( 3-oxo-4-morpholinyl) - phenyl] -1,3-oxazolidin-5-yl} -methyl) -2- thiophencarboxamid
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20090076104A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched losartan
WO2010059529A2 (en) * 2008-11-19 2010-05-27 Merial Limited Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN107617107A (zh) * 2017-09-18 2018-01-23 浙江大学 一种复方血管紧张素转换酶类抗瘢痕制剂
CN107648611A (zh) * 2017-09-18 2018-02-02 浙江大学 复方血管紧张素转换酶类抗瘢痕外用制剂
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途
CN120093759B (zh) * 2025-02-24 2026-04-14 华中科技大学同济医学院附属同济医院 一种预防或治疗动脉硬化的药物组合物及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986007056A1 (en) * 1985-05-21 1986-12-04 Pfizer Inc. Hypoglycemic thiazolidinediones
DE3536687A1 (de) * 1985-10-15 1987-04-16 Hoechst Ag Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit
US5231080A (en) 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
DE3925759A1 (de) * 1989-08-03 1991-02-07 Thera Patent Verwaltungs Gmbh Verwendung von ace-inhibitoren fuer die atheroskleroseprophylaxe
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
CA2026686A1 (en) 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
GB2241890A (en) 1990-03-12 1991-09-18 Squibb & Sons Inc Preventing onset of or treating protein catabolism using an ace inhibitor
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2229000C (en) * 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CA2118706A1 (en) * 1992-07-13 1994-01-20 Saizo Shibata Novel thiazolidinedione compounds and use thereof
JPH0741423A (ja) 1993-02-24 1995-02-10 Sankyo Co Ltd 動脈硬化症治療剤
WO1994019347A1 (fr) * 1993-02-24 1994-09-01 Sankyo Company, Limited Remede contre l'arteriosclerose
DE4318813A1 (de) * 1993-06-07 1994-12-08 Merck Patent Gmbh Imidazopyridine
NO303782B1 (no) * 1994-03-23 1998-08-31 Sankyo Co Tiazolidin- og oksazolidinderivater og farmas°ytiske preparater inneholdende slike, samt deres anvendelse til fremstilling av medikamenter
EP0754042A4 (de) * 1994-03-29 2004-06-23 Merck & Co Inc Behandlung von atherosklerose mit imidazolen, die den angiotensin ii-rezeptor blockieren
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NZ330774A (en) 1996-04-05 1999-06-29 Takeda Chemical Industries Ltd Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity

Also Published As

Publication number Publication date
CZ10299A3 (cs) 1999-06-16
CZ299162B6 (cs) 2008-05-07
PT930076E (pt) 2005-01-31
EP1175902B1 (de) 2005-10-19
US6610682B2 (en) 2003-08-26
WO1998002183A1 (fr) 1998-01-22
DK1175902T3 (da) 2005-12-19
CA2261040C (en) 2009-01-20
CN1476833A (zh) 2004-02-25
KR100540618B1 (ko) 2006-01-12
HUP9903166A3 (en) 2003-09-29
NO334217B1 (no) 2014-01-13
DE69734405T2 (de) 2006-08-03
AU714618B2 (en) 2000-01-06
US20020013308A1 (en) 2002-01-31
HU225415B1 (en) 2006-11-28
ES2250283T3 (es) 2006-04-16
ES2232873T3 (es) 2005-06-01
CZ300089B6 (cs) 2009-01-28
DE69734405D1 (de) 2006-03-02
HUP9903166A2 (hu) 2000-09-28
HU227399B1 (en) 2011-05-30
NZ333723A (en) 2000-09-29
CN1230122A (zh) 1999-09-29
CA2261040A1 (en) 1998-01-22
KR20000023757A (ko) 2000-04-25
NO20056021L (no) 1999-03-15
CN1155409C (zh) 2004-06-30
HUP0600501A3 (en) 2008-10-28
DK0930076T3 (da) 2005-01-31
NO990166D0 (no) 1999-01-14
HU0600501D0 (en) 2006-08-28
ATE283704T1 (de) 2004-12-15
DE69731840D1 (de) 2005-01-05
HK1020260A1 (en) 2000-04-07
EP1175902A1 (de) 2002-01-30
EP0930076A4 (de) 2001-10-04
IL128059A0 (en) 1999-11-30
DE69731840T2 (de) 2005-08-04
RU2183128C2 (ru) 2002-06-10
IL145758A (en) 2006-06-11
CN1221259C (zh) 2005-10-05
EP0930076A1 (de) 1999-07-21
IL128059A (en) 2003-12-10
EP0930076B1 (de) 2004-12-01
NO990166L (no) 1999-03-15
AU3459597A (en) 1998-02-09
NO322314B1 (no) 2006-09-11
RU2220723C2 (ru) 2004-01-10

Similar Documents

Publication Publication Date Title
DE69734405D1 (de) Verwendung von CS-866 (Olmersartan) zur Herstellung eines Medikaments für die Behandlung von Arteriosklerose
ATE97801T1 (de) Mittel zur oralen verwendung.
RU2001126527A (ru) Средство и способ лечения или профилактики артериосклероза
DE69525354D1 (de) Eine neuartige medizinische verwendung eines 5ht 3-antagonisten
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
DE69506686D1 (de) Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase
DE60035059D1 (de) Mittel zur verbesserung der hauttextur
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE38836T1 (de) Substituierte benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln.
ATA232687A (de) Zahnpflegemittel, sowie verfahren zur herstellung des zahnpflegemittels
ATE191142T1 (de) Verwendung von phenalkylaminen zur herstellung von cholesterinsenkenden arzneimitteln
ATE135220T1 (de) Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose
DE3768150D1 (de) Verwendung eines 1,3-oxazolidin-2-on-derivates zur herstellung eines arzneimittels zur behandlung von ischaemie.
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
BR0212143A (pt) Composição para lavagem bucal para tratamento ou prevenção de infecção por bactérias ou fungos
ATE307587T1 (de) Verwendung von thiaminen zur herstellung eines arzneimittels zur prophylaxe und zur therapie der diabetischen retinopathie und der diabetischen nephropathie
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
ATE183390T1 (de) Verwendung einer kombination von antineoplastonen zur herstellung eines arzneimittels zur behandlung der neurofibromatose
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE59504374D1 (de) Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
DE59709081D1 (de) Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung und Prävention der Alzheimer'schen Krankheit
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE68920022D1 (de) Indolessigsäure-derivate, verfahren zur herstellung sowie arzneimittel, die diese als aktive mittel enthalten.
ATE192336T1 (de) Verwendung von bifemelan zur herstellung eines arzneimittels zur behandlung der hyperkinesie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1175902

Country of ref document: EP